Identification of biomarkers and therapeutic targets for renal cell cancer using ProteinChip technology;Identifizierung von biomarkern und therapeutischen targets beim nierenzellkarzinom mittels ProteinChip-technologie

Urologe - Ausgabe A

Volumn 45, Issue 3, 2006, Pages 305-315

  Junker, K ^a,b   Von Eggeling, F ^a   Muller J ^a   Steiner, T ^a   Schubert, J ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

ProteinChip technology; Renal cell tumours; Specific biomarkers; Tumour biology

Indexed keywords

BIOLOGICAL MARKER; DNA; PROTEOME; RNA; SERUM AMYLOID A;

HIGH THROUGHPUT SCREENING; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; PATIENT SELECTION; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN MICROARRAY; PROTEOMICS; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

CARCINOMA, RENAL CELL; COMPUTATIONAL BIOLOGY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HUMANS; KIDNEY NEOPLASMS; PROGNOSIS; PROTEIN ARRAY ANALYSIS;

EID: 33645089664     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-006-1001-2     Document Type: Review

References (31)

1. Adam BL, Qu Y, Davis JW et al. (2002) Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62: 3609-3614
2. Banerjee H, Hawkins Z, Williams J et al. (2004) Search for a novel biomarker for the brain cancer astrocytoma by using surface enhanced laser desorption/ionisation (SELDI) technique. Cell Mol Biol (Noisy-le-grand) 50: 733-736
3. Britten RA, Hardy C, Vlahou A, Gregory B, Giri PS, Drake R (2005) Identification of reproducible low mass SELDI protein profiles specific to cisplatin resistance in human ovarian cancer cells. Oncol Rep 14: 1323-1330
4. Cadieux PA, Beiko DT, Watterson JD et al. (2004) Surface-enhanced laser desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS): a new proteomic urinary test for patients with urolithiasis. J Clin Lab Anal 18: 170-175
5. Clarke W, Silverman BC, Zhang Z, Chan DW, Klein AS, Molmenti EP (2003) Characterization of renal allograft rejection by urinary proteomic analysis. Ann Surg 237: 660-665
6. Combaret V, Bergeron C, Brejon S, Iacono I, Perol D, Negrier S, Puisieux A (2005) Protein chip array profiling analysis of sera from neuroblastoma patients. Cancer Lett 228: 91-96
7. Ernst G, Melle C, Schimmel B, Bleul A, von Eggeling F (2006) Proteohistography - Direct analysis of tissue with high sensitivity and high spatial resolution using ProteinChip technology. J Histochem Cytochem 54: 13-17
8. Fetsch PA, Simone NL, Bryant-Greenwood PK et al. (2002) Proteomic evaluation of archival cytologic material using SELDI affinity mass spectrometry: potential for diagnostic applications. Am J Clin Pathol 118: 870-876
9. Heike Y, Hosokawa M, Osumi S et al. (2005) Identification of serum proteins related to adverse effects induced by docetaxel infusion from protein expression profiles of serum using SELDI ProteinChip system. Anticancer Res 25: 1197-1203
10. Junker K, Gneist J, Melle C, Driesch D, Schubert J, Claussen U, von Eggeling F (2005) Identification of protein pattern in kidney cancer using ProteinChip arrays and bioinformatics. Int J Mol Med 15: 285-290
11. Khan N, Cromer CJ, Campa M, Patz EF Jr (2004) Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma. Cancer 101: 379-384
12. Kong F, Nicole White C et al. (2005) Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer. Gynecol Oncol 2005
13. Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R (2005) Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 5: 4589-4596
14. Krieg RC, Fogt F, Braunschweig T, Herrmann PC, Wollscheidt V, Wellmann A (2004) ProteinChip Array analysis of microdissected colorectal carcinoma and associated tumor stroma shows specific protein bands in the 3.4 to 3.6 kDa range. Anticancer Res 24: 1791-1796
15. Le L, Chi K, Tyldesley S, Flibotte S, Diamond DL, Kuzyk MA, Sadar MD (2005) Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem 51: 695-707
16. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW (2002) Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48: 1296-1304
17. Liu W, Guan M, Wu D, Zhang Y, Wu Z, Xu M, Lu Y (2005) Using tree analysis pattern and SELDI-TOF-MS to discriminate transitional cell carcinoma of the bladder cancer from noncancer patients. Eur Urol 47: 456-462
18. Melle C, Kaufmann R, Hommann M, Bleul A, Driesch D, Ernst G, von Eggeling F (2004) Proteomic profiling in microdissected hepatocellular carcinoma tissue using ProteinChip technology. Int J Oncol 24: 885-891
19. Mueller J, von Eggeling F, Driesch D, Schubert J, Melle C, Junker K (2005) ProteinChip technology reveals distinctive protein expression profiles in the urine of bladder cancer patients. Eur Urol 47: 885-894
20. O'Riordan E, Goligorsky MS (2005) Emerging studies of the urinary proteome: the end of the beginning? Curr Opin Nephrol Hypertens 14: 579-585
21. Petricoin EF 3rd, Ornstein DK, Paweletz CP et al. (2002) Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 94: 1576-1578
22. Petricoin EF, Ardekani AM, Hitt BA et al. (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359: 572-577
23. Pusztai L, Gregory BW, Baggerly KA et al. (2004) Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer 100: 1814-1822
24. Rogers MA, Clarke P, Noble J, Munro NP, Paul A, Selby PJ, Banks RE (2003) Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res 63: 6971-6983
25. Rossi L, Martin BM, Hortin GL et al. (2005) Inflammatory protein profile during systemic high dose interleukin-2 administration. Proteomics 5: 2385-2395
26. Schaub S, Rush D, Wilkins J et al. (2004) Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J Am Soc Nephrol 15: 219-227
27. Schaub S, Wilkins J, Weiler T, Sangster K, Rush D, Nickerson P (2004) Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int 65: 323-332
28. Tolson J, Bogumil R, Brunst E et al. (2004) Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 84: 845-856
29. Won Y, Song HJ, Kang TW, Kim JJ, Han BD, Lee SW (2003) Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons. Proteomics 3: 2310-2316
30. Wong YF, Cheung TH, Lo KW, Wang VW, Chan CS, Ng TB, Chung TK, Mok SC (2004) Protein profiling of cervical cancer by protein-biochips: proteomic scoring to discriminate cervical cancer from normal cervix. Cancer Lett 211: 227-234
31. Yokoi K, Shih LC, Kobayashi R et al. (2005) Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer. Int J Oncol 27: 1361-1369